Abstract
The use of donor T cells expressing a suicide gene for destruction of graft-versus-host effector cells provides a tool for alloreactivity modulation. We describe a case of extensive vitiligo that developed after ganciclovir treatment of cutaneous chronic graft-versus-host disease in a patient who had received donor T lymphocytes expressing herpes simplex virus thymidine kinase at the time of transplantation.
Publication types
-
Case Reports
-
Clinical Trial
-
Clinical Trial, Phase I
-
Clinical Trial, Phase II
-
Letter
-
Multicenter Study
MeSH terms
-
Adult
-
Antiviral Agents / adverse effects*
-
Antiviral Agents / therapeutic use
-
Bone Marrow Transplantation
-
Ganciclovir / adverse effects*
-
Ganciclovir / therapeutic use
-
Graft vs Host Disease / drug therapy*
-
Humans
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
-
Male
-
Simplexvirus / enzymology*
-
T-Lymphocytes / transplantation*
-
Thymidine Kinase / metabolism*
-
Vitiligo / chemically induced*
Substances
-
Antiviral Agents
-
Thymidine Kinase
-
Ganciclovir